01 January 2008
Therapeutic drug monitoring of sirolimus and everolimus
E.M. BillaudAnn Transplant 2008; 13(1): 26-26 :: ID: 880180
Abstract
Sirolimus (SRL) (rapamycine) and everolimus (RAD), 40-hydroxy-rapamycine, were recently introduced as proliferation signal inhibitors (PSI) immunosuppressants, acting on the mTOR (target of rapamycine) IL2 synthesis. Due to different development strategies, SRL was registered in renal transplantation with steroids and cyclosporine (CyA) for the first three months, whereas RAD both in renal and cardiac transplantation with steroids and (reduced doses) CyA. Therapeutic drug monitoring (TDM) was recommended to control the enhancement of CyA nephrotoxicity and document RAD therapeutic detectable levels. Target trough concentration range were defined respectively as 3-8 and 4-12 ng/mL for RAD and SRL, the latest increased after CyA withdrawal [12-20]. Dose regimen are 2-5 mg QD (SRL) and 0.75 mg BID (RAD), taking in account the inhibition of CyA on PSI metabolism. Security profile exhibited hyperlipidemia, haematotoxicity, and more specific side effects (interstitial pneumopathy, lymphoceles and mucositis). Pharmacokinetics particularities of these lipophilic drugs resulted in long half-lives, poor bioavailability, intensive metabolism and numerous pharmacokinetic CYP3A4 drug interactions. Interindividual variability appeared more important than intraindividual. PSI exhibited similar pharmacodynamics but RAD appeared easiest to manage in clinical practice, due to its reduced halflife (30 h) as compared to SRL (60 h). TDM is performed using LC-MS/MS, but immunoassays are available from Abbott (MEIA, SRL) and Seradyn (Innofluor FPIA, RAD), exhibiting cross reactions (>80%) with metabolites and between PSI. International proficiency testing schemes are available (www.bioanalytics.uk). The place of these drugs in the immunosuppressive strategy has to be settled in the future, specially regarding delayed graft dysfunction prevention.
Keywords: Sirolimus, Everolimus, immunosuppressants
In Press
07 Mar 2024 : Original article
Outcomes of Renal Transplantation in ANCA-Associated VasculitisAnn Transplant In Press; DOI: 10.12659/AOT.943433
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860